A clinical briefing on the Estrogens, Esterified supply situation for providers. Includes shortage timeline, prescribing implications, and alternatives.
If your patients have been reporting difficulty filling Estrogens, Esterified (Menest) prescriptions, this briefing provides the clinical and logistical context you need to guide them through the current supply landscape.
While Estrogens, Esterified may not be on the FDA's active shortage list, real-world availability has been inconsistent — and the broader HRT supply chain disruptions of the past several years continue to affect oral estrogen products.
Understanding the broader context is essential for managing patient expectations:
The FDA reported a shortage of Estradiol Valerate injection beginning August 2016, resolved by June 2017. This was an early signal of vulnerabilities in estrogen manufacturing capacity.
Pfizer discontinued the 2.5 mg strength of Menest (Estrogens, Esterified), reducing available dosage options. The original brand Estratab had already been discontinued prior to this.
Manufacturing constraints, increased demand for HRT driven by greater menopause awareness, and supply chain disruptions led to shortages across multiple estrogen products — including estradiol patches, injectable formulations, and conjugated estrogens.
As patch and injectable shortages persisted, prescribers increasingly moved patients to oral estrogen products. This demand shift put pressure on Estrogens, Esterified and other oral formulations, leading to intermittent availability gaps.
Supply has improved but remains uneven across geographies. Independent pharmacies and certain wholesalers report better access than large chain pharmacies, where automated ordering systems may not prioritize lower-volume medications.
The current supply environment raises several considerations for prescribers:
Most Estrogens, Esterified prescriptions are filled with generic esterified estrogen tablets. Brand-name Menest (Pfizer) is available but typically at a significantly higher cost. Specifying "DAW" (Dispense as Written) for brand-name Menest may further limit availability, so allowing generic substitution is recommended when clinically appropriate.
Available strengths are 0.3 mg, 0.625 mg, and 1.25 mg. If a specific strength is unavailable, consider whether an alternative dosing strategy using an available strength is clinically appropriate. For example, two 0.3 mg tablets may substitute for 0.625 mg in some patients, though this should be evaluated on a case-by-case basis.
For patients with an intact uterus, concurrent progestin therapy remains essential to mitigate endometrial cancer risk. If switching patients to a different estrogen product, ensure the progestin component of their regimen is also adjusted appropriately.
Based on current market intelligence:
Affordability affects adherence. Here's the current pricing landscape:
For a detailed cost guide to share with patients, see: How to Save Money on Estrogens, Esterified.
Medfinder's provider tools allow you to help patients locate pharmacies with Estrogens, Esterified in stock. This can be integrated into your workflow when you learn that a patient's pharmacy is unable to fill a prescription.
When switching is necessary, the following alternatives are clinically well-established:
For a patient-facing alternatives overview: Alternatives to Estrogens, Esterified.
In November 2025, the FDA initiated removal of boxed warnings related to cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy products. The endometrial cancer boxed warning for systemic estrogen-alone products remains. These label changes may influence prescribing decisions and patient acceptance of HRT.
The estrogen supply chain is gradually recovering, but the concentration of manufacturing among few producers makes ongoing vigilance important. Key developments to monitor:
The Estrogens, Esterified supply situation requires proactive management. Having a therapeutic alternative ready, leveraging tools like Medfinder for providers, and keeping patients informed about their options can prevent gaps in care.
For a patient-oriented overview of the current shortage, you may direct patients to: Estrogens, Esterified Shortage Update for Patients.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
